Breast cancer
Education on breast cancer and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between breast cancer and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is breast cancer?
Breast cancer is a group of diseases in which cells in breast tissue grow abnormally. Established risk factors, screening, and treatments are defined by oncology guidelines and organizations such as the National Cancer Institute. If you have questions about diagnosis or treatment, work with your oncology team.
The Mark Egly Foundation does not replace cancer care. We focus on Alpha-1 Antitrypsin Deficiency (AATD) education and research questions that may intersect with inflammation and tissue protection.
How this may relate to Alpha-1 (hypothesis)
Alpha-1 Antitrypsin (AAT) is a protective protein. In classic AATD, low or dysfunctional AAT is linked to lung and liver disease. Mark Egly's patent explores whether low circulating AAT and excess neutrophil elastase may also influence pathways involved in tumor biology, including in breast tissue.
The patent discusses AAT together with thrombospondin-1 (TSP1), a protein involved in regulating new blood vessel growth. It proposes that healthier circulating AAT may support protective biology in lung and breast tissue. That proposal is a research hypothesis, not a proven treatment path for anyone with breast cancer.
What Mark Egly's patent discusses about breast cancer
The patent names many forms of breast cancer, including metastatic breast cancer (MBC), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer, inflammatory breast cancer (IBC), medullary, tubular carcinoma, mucinous carcinoma, Paget disease, and small cell and non-small cell presentations of breast cancer.
It notes that smoking can reduce AAT and that secondhand smoke is associated with some cancer risk discussions in the literature. Those observations sit alongside the patent's broader claim that restoring healthier AAT levels might reduce injury from excess neutrophil activity. Independent clinical validation is still required.
Sibling pages in our catalog
- Metastatic breast cancer
- Inflammatory breast cancer
- Triple negative breast cancer
- Ductal carcinoma in situ
- Invasive ductal carcinoma
See also our hub: AATD and cancer prevention research.
What you can do
- Follow your oncology team's plan for screening, diagnosis, and treatment.
- Learn established AATD facts on What is Alpha-1 Antitrypsin Deficiency.
- Discuss AAT testing with a clinician if you have unexplained lung or liver disease or a family history of AATD.
- Read Mark's patent overview for research context.
- Support research funding if you want more independent study of these questions.
Additional resources: